Identifying subtypes of chronic kidney disease with machine learning: development, internal validation and prognostic validation using linked electronic health records in 350,067 individuals
Source check: Source checked. Not independent scientific confirmation.
Finding: Seven unsupervised clustering methods on linked EHR features identified five CKD profiles; XGBoost predicted subtype labels. Across incident and prevalent CKD cohorts (350,067 and 195,422), five profiles (early-onset, late-onset, cancer, metabolic, cardiometabolic) differed in 5-year mortality, admissions and incident chronic disease. Cardiometabolic incident subtype had highest 5-year mortality/admission risks; this is observational prognostic stratification, not causal etiology. Population-based UK EHR development; internal clustering/method consistency and prognostic validation across linked outcomes. No independent external geography validation, a limitation stated by authors. This record is limited to the study result and does not establish independent replication or real-world benefit.
Technology: Unsupervised clustering and XGBoost
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Seven unsupervised clustering methods on linked EHR features identified five CKD profiles; XGBoost predicted subtype labels.
- Test and result
- Seven unsupervised clustering methods on linked EHR features identified five CKD profiles; XGBoost predicted subtype labels. Across incident and prevalent CKD cohorts (350,067 and 195,422), five profiles (early-onset, late-onset, cancer, metabolic, cardiometabolic) differed in 5-year mortality, admissions and incident chronic disease. Cardiometabolic incident subtype had highest 5-year mortality/admission risks; this is observational prognostic stratification, not causal etiology. Population-based UK EHR development; internal clustering/method consistency and prognostic validation across linked outcomes. No independent external geography validation, a limitation stated by authors.
- Limitation / still unknown
- The source-checked evidence does not establish broader external validity or prospective benefit. Affiliation was not available in the retrieved trusted primary metadata. Organization affiliation was not stated in the source material reviewed. Affiliation was not stated in the reviewed material.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC9989643/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.